External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul><li>Clarity have released further data from their Phase II COBRA trial evaluating their 64Cu-SAR- bisPSMA PET diagnostic agent in suspected biochemical recurrent (BCR) prostate cancer.</li><li>Recently reported data was met by the market with mixed reviews, and highlighted the challenge Clarity have ahead of them in proving out the potential of their Dx agent versus approved PET agents (as it looked too good to be true).</li><li>Given the strong sensitivity and specificity reported in their PROPELLER trial (vs other agents in primary staging) and the next-day imaging functionality (and overall logistical benefits), we remain positive on 64Cu-SAR-bisPSMA to offer distinct advantages to other agents. In terms of overall superiority, we of course need to wait to see this proven now in a Phase III registrational program – which is being planned as we write. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Clarity have released further data from their Phase II COBRA trial evaluating their 64Cu-SAR- bisPSMA PET diagnostic agent in suspected biochemical recurrent (BCR) prostate cancer.Recently reported data was met by the market with mixed reviews, and highlighted the challenge Clarity have ahead of them in proving out the potential of their Dx agent versus approved PET agents (as it looked too good to be true).Given the strong sensitivity and specificity reported in their PROPELLER trial (vs other agents in primary staging) and the next-day imaging functionality (and overall logistical benefits), we remain positive on 64Cu-SAR-bisPSMA to offer distinct advantages to other agents. In terms of overall superiority, we of course need to wait to see this proven now in a Phase III registrational program – which is being planned as we write. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - Lesion Size: A New Potential Differentiator